Efficacy and safety of calcitonin gene‐related peptide antagonists in migraine treatment: A meta‐analysis

Efficacy and safety of calcitonin gene‐related peptide antagonists in migraine treatment: A meta‐analysis

Abstract Introduction We systematically reviewed the efficacy and safety of Calcitonin Gene‐Related Peptide (CGRP) antagonists for migraine treatment. Methods Various databases including PubMed, Embase, The Cochrane Library, Chinese National Knowledge Infrastructure (CNKI), WanFang Data were electro...

Full description

Bibliographic Details
Main Authors:	Tingting Huang, Yang Xu, Yajie Chen, Jing Bian, Zhaohu Chu, Shoucai Zhao, Lingsong Ma
Format:	Article
Language:	English
Published:	Wiley 2022-04-01
Series:	Brain and Behavior
Subjects:	CGRP antagonists migraine meta‐analysis randomized controlled trial
Online Access:	https://doi.org/10.1002/brb3.2542

Similar Items

Calcitonin gene relating peptide inhibitors in combination for migraine treatment: A mini-review
by: Tulsi Shah, et al.
Published: (2023-03-01)

Constipation Caused by Anti-calcitonin Gene-Related Peptide Migraine Therapeutics Explained by Antagonism of Calcitonin Gene-Related Peptide’s Motor-Stimulating and Prosecretory Function in the Intestine
by: Peter Holzer, et al.
Published: (2022-01-01)

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
by: Damiana Scuteri, et al.
Published: (2019-04-01)

Effects of monoclonal antagonist antibodies on calcitonin gene-related peptide receptor function and trafficking
by: Raffi Manoukian, et al.
Published: (2019-04-01)

Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database
by: Alexandre O. Gérard, et al.
Published: (2022-05-01)

Nutrition and Calcitonin Gene Related Peptide (CGRP) in Migraine
by: Michal Fila, et al.
Published: (2023-01-01)

Potential use of microRNA-590 biomarkers verses plasma calcitonin gene-related peptide for diagnosis of migraine
by: Hany Mohamed El Deeb, et al.
Published: (2024-02-01)

Effect of soy isoflavones supplementation on migraine characteristics, mental status and calcitonin gene-related peptide (CGRP) levels in women with migraine: results of randomised controlled trial
by: Maedeh Babapour, et al.
Published: (2022-07-01)

Serum calcitonin gene related peptide (CGRP) levels in migraine: A study on its clinical correlation and diagnostic efficacy
by: Sofia Khatoon, et al.
Published: (2021-09-01)

The Management of High-Frequency Episodic and Chronic Migraines with Calcitonin Gene-Related Peptide Monoclonal Antibody
by: Larisa A. Dobrynina, et al.
Published: (2023-06-01)

Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial
by: Todd J. Schwedt, et al.
Published: (2023-11-01)

Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials
by: Virginia L. Stauffer, et al.
Published: (2020-06-01)

The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis
by: Min Hou, et al.
Published: (2017-04-01)

Commentary: Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and prosecretory function in the intestine
by: Kimberly D. Mackenzie, et al.
Published: (2022-11-01)

Calcitonin gene-related peptide facilitates sensitization of the vestibular nucleus in a rat model of chronic migraine
by: Yun Zhang, et al.
Published: (2020-06-01)

Epigenetic Connection of the Calcitonin Gene-Related Peptide and Its Potential in Migraine
by: Michal Fila, et al.
Published: (2022-05-01)

Trajectory of blood pressure after initiating anti-calcitonin gene-related peptide treatment of migraine: a target trial emulation from the veterans health administration
by: Kaicheng Wang, et al.
Published: (2023-08-01)

Real-World Use of Ubrogepant as Acute Treatment for Migraine with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody: Results from COURAGE
by: Richard B. Lipton, et al.
Published: (2023-11-01)

Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway
by: Zifan Zhou, et al.
Published: (2023-11-01)

Long-Term Treatment with the Calcitonin Gene-Related Peptide Receptor Antagonist Erenumab in CADASIL: Two Case Reports
by: Maria Albanese, et al.
Published: (2024-03-01)

Erenumab: A novel calcitonin gene-related peptide receptor antagonist developed specifically for migraine prevention
by: Shuchita Garg, et al.
Published: (2020-01-01)

Calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraines in adults
by: Eric R Ocheretyaner, et al.
Published: (2022-10-01)

Editorial: Calcitonin Gene-Related Peptide: Novel Biology and Treatments
by: Susan D. Brain, et al.
Published: (2022-07-01)

CGRP-targeted medication in chronic migraine - systematic review
by: Renato Oliveira, et al.
Published: (2024-04-01)

Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials
by: Xinxin Deng, et al.
Published: (2024-02-01)

Calcitonin Gene–Related Peptide Monoclonal Antibody Versus Botulinum Toxin for the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment Comparison
by: Jiajie Lu, et al.
Published: (2021-05-01)

Gepants for abortive treatment of migraine: A network meta‐analysis
by: Peiwei Hong, et al.
Published: (2020-08-01)

The effects of vitamin D supplementation on interictal serum levels of calcitonin gene-related peptide (CGRP) in episodic migraine patients: post hoc analysis of a randomized double-blind placebo-controlled trial
by: Zeinab Ghorbani, et al.
Published: (2020-02-01)

Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study
by: Varnado OJ, et al.
Published: (2024-01-01)

Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review
by: Jean Schoenen, et al.
Published: (2023-08-01)

Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
by: Mark E. Bangs, et al.
Published: (2020-01-01)

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
by: Angelo Camporeale, et al.
Published: (2018-11-01)

Real-world efficacy and tolerability of fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, observational study
by: Christopher Kjaer Cullum, et al.
Published: (2023-08-01)

Calcitonin gene related peptide and its functions
by: Karimian M
Published: (1998-07-01)

CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine
by: Matilde Capi, et al.
Published: (2021-04-01)

Unmet Needs in Preventive Treatment of Migraine
by: Enrico Bentivegna, et al.
Published: (2023-02-01)

The Neuropeptide α-Calcitonin Gene-Related Peptide as the Mediator of Beneficial Effects of Exercise in the Cardiovascular System
by: Tom Skaria, et al.
Published: (2022-03-01)

Analysis of the DNA methylation pattern of the promoter region of calcitonin gene-related peptide 1 gene in patients with episodic migraine: An exploratory case-control study
by: Elisa Rubino, et al.
Published: (2022-01-01)

CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
by: Valentina Favoni, et al.
Published: (2019-03-01)

Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments
by: George R. Nissan, et al.
Published: (2022-07-01)